EGFR and non-small cell lung carcinoma: Among these, EGFR, being one of the more prevalent mutation genes in NSCLC patients, has seen a continuous evolution of EGFR tyrosine kinase inhibitors (TKIs), significantly improving the survival time of EGFR-positive patients.